Incidence of metabolic syndrome in systemic lupus erythematosus and its influence by glucocorticoids
10.3760/cma.j.issn.0578-1426.2012.06.010
- VernacularTitle:系统性红斑狼疮患者代谢综合征的发生及其与糖皮质激素应用的关系
- Author:
Shengyun LIU
;
Jinyan GUO
;
Lei ZHANG
;
Zhangsuo LIU
;
Zhaohui ZHENG
;
Genyang CHENG
;
Guanmin GAO
;
Xin ZHANG
;
Guizhi LIU
;
Xiaofeng ZENG
- Publication Type:Journal Article
- Keywords:
Lupus erythematosus,systemic;
Metabolic syndrome X;
Glucocorticoids
- From:
Chinese Journal of Internal Medicine
2012;51(6):441-444
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the incidence and correlative factors of metabolic syndrome (MS) in patients with systemic lupus erythematosus (SLE).Methods A total of 116 SLE patients and 115 controls were enrolled into the study.The incidence of MS,SLE disease activity index(SLEDAI) of patients with SLE combined with MS (MS-SLE) and patients without MS (n-MS-SLE),lupus characteristics,cumulative glucocorticoids,administration dose of glucocorticoids and hydroxychloroquine were compared between SLE group and the control group.Results The incidence of MS of SLE group was obviously higher than that of the control ( 34.48％ vs 14.78％,P ＜ 0.05 ).The ratios of patients with lower HDL-C,higher TG and higher blood pressure in SLE group ( 50.86％,56.03％,46.55％ ) were higher than those in the controls ( 34.78％,16.52％,20.00％,all P ＜ 0.05 ).MS-SLE group had significantly higher mean waist circumference,BMI,systolic blood pressure and diastolic blood pressure and lower HDL-C than n-MS-SLE group (all P ＜0.05 ).No significant difference was found regarding duration of disease,renal involvement,ESR,C-reactive protein,high-sensitivity C-reactive protein,SLEDAI,cumulative and current glucocorticoids use in MS-SLE group and n-MS-SLE group.The ratio of patients taking hydroxychloroquine in n-MS-SLE group was higher than that of MS-SLE group (46.05％ vs 15.00％,P＜0.05).Conclusions Patients with SLE has a higher incidence rate of MS.Hydroxychloroquine may reduce their MS incidence.
